期刊文献+

特发性肺动脉高压患者血浆骨形成蛋白-2的变化及其临床意义 被引量:1

原文传递
导出
摘要 目的:检测特发性肺动脉高压(IPAH)患者血浆骨形成蛋白2(BMP-2)的浓度,并分析其与肺动脉压力的相关性。方法:住院IPAH患者28例,正常对照组20例,采用ELISA法测定血浆中BMP-2的浓度,同时对28例IPAH患者经右心漂浮导管检测肺动脉压力。结果:正常对照组血浆BMP-2的水平为(0.0898±0.0295)mg/L,IPAH组为(0.1294±0.0292)mg/L,2组比较,P<0.01。IPAH患者的平均肺动脉压力和血浆BMP-2水平呈正相关(r=0.625,P<0.01)。结论:IPAH患者血浆中的BMP-2水平增高,并与肺动脉压力有一定相关性。
出处 《临床心血管病杂志》 CSCD 北大核心 2008年第3期225-226,共2页 Journal of Clinical Cardiology
  • 相关文献

参考文献7

  • 1COOL C D, STEWART J S, WERAHERA P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cellspecific marlcer: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth [J]. Am J Pathol, 1999, 155:411-419.
  • 2SPINELLA-JAEGLE S, ROMAN -ROMAN S, FAUCHEU C, et al. Opposite effects of bone morphogenetic protein-2 and transforming growth factor beta 1 on osteoblast differentiation[J]. Bone, 2001, 29:323-330.
  • 3TEICHERT-KULISZEWSKA K, KUTRYK M J, KULISZEWSKI M A, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-offunction mutations in the pathogenesis of pulmonary hypertension[J]. Circ Res, 2006, 98: 209-217.
  • 4SIMONNEAU G, GALIE N, RUBIN L J, et al. Clinical classification of pulmonary hypertension[J] . Am Coll Cardiol, 2004 ,43:5S-12S.
  • 5PICCOLO S, AGIUS E, LEYNS L, et al. The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals[J]. Nature,1999, 397: 707-710.
  • 6WONG G A, TANG V, EI-SABEAWY F, et al. BMP-2 inhibits proliferation of human aortic smooth muscle ceils via p21 [J]. Am J Physiol Endocriol Metab, 2003, 284:E972-E979.
  • 7DENG Z, MORSE J H, SLAGER S L, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-Ⅱ gene[J]. Am J Hum Genet, 2000, 67:737-744.

同被引文献10

  • 1Voelkel NF,Quaife RA,Leinwand LA,et al. Right ventricular function and failure: report of a National Heart,Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure[J]. Circulation,2006,114(17):1883-91.
  • 2Ndip A,Williams A,Jude EB,et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy[J].Diabetes 2011,60(8):2187-96.
  • 3Teichert-kuliszewska K,Kutryk MJ,Kuliszewski MA,et al. Bone morphogenetie protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension[J]. Circ Res,2006,98(2):209-17.
  • 4Simonneau G,Galie N,Rubin LJ,et al. Clinical classification of pulmonary hypertension[J] .Am Coil Cardiol,2004,43(12 Suppl S):5S-12S.
  • 5Cowie MR,Struthers AD,Wood DA,et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care[J]. Lancet, 1997,350(9088): 1349-53.
  • 6Andreassen AK,Wergeland R,Simonsen S,et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hyperteusion[J]. Am J Cardiol,2006,98(4):525-9.
  • 7Brun H,Holmstrom H,Thaulow E,et al. Patients with pulmonary hypertension related to congenital systemic-topulmonary shunts are characterized by inflammation involving endothelial cell activation and platelet-mediated inflammation[J]. Congenit Heart Dis,2009;4(3): 153-9.
  • 8Simonet WS,Lacey DL,Dunstan CR,et al. Osteoprotegerin:a novel secreted protein involved in the regulation of bone density[J]. Cell, 1997,89(2):309-19.
  • 9Blazquez-Medela A,Lopez-Novoa J,Martinez-Salgado C.et al. Osteoprotegerin andDiabetes-Associated Pathologies[J]. Current Molecular Medicine,2011 ( 16):401 - 16.
  • 10Condliffe R, Pickworth JA, Hopkinson K,et al. Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hvoertension[J]. Pulm Circ,2012(21 ):21-7.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部